Can a simple arthritis drug tame CAR-T's brain risks?
Disease control
Completed
This study tested whether adding the drug anakinra to standard CAR-T cell therapy could reduce serious brain side effects in people with relapsed or refractory non-Hodgkin lymphoma. Fifteen participants received the combination. The goal was to see if anakinra could lower the rat…
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC